JP6968090B2 - Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 - Google Patents

Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 Download PDF

Info

Publication number
JP6968090B2
JP6968090B2 JP2018551327A JP2018551327A JP6968090B2 JP 6968090 B2 JP6968090 B2 JP 6968090B2 JP 2018551327 A JP2018551327 A JP 2018551327A JP 2018551327 A JP2018551327 A JP 2018551327A JP 6968090 B2 JP6968090 B2 JP 6968090B2
Authority
JP
Japan
Prior art keywords
alkyl
disorders
formula
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018551327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512533A5 (enExample
JP2019512533A (ja
Inventor
ルイ ロベール ドリニー、ミカエル
ポール ヘール、ジャグ
ケヤエルツ、ジャン
エルサ ルピシエール、ルース
アリグザンダー ロウ、マーティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2019512533A publication Critical patent/JP2019512533A/ja
Publication of JP2019512533A5 publication Critical patent/JP2019512533A5/ja
Application granted granted Critical
Publication of JP6968090B2 publication Critical patent/JP6968090B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018551327A 2016-04-01 2017-03-31 Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体 Active JP6968090B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163579 2016-04-01
EP16163579.2 2016-04-01
PCT/EP2017/057767 WO2017167994A1 (en) 2016-04-01 2017-03-31 Fused pentacyclic imidazole derivatives as modulators of tnf activity

Publications (3)

Publication Number Publication Date
JP2019512533A JP2019512533A (ja) 2019-05-16
JP2019512533A5 JP2019512533A5 (enExample) 2020-04-23
JP6968090B2 true JP6968090B2 (ja) 2021-11-17

Family

ID=55650327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018551327A Active JP6968090B2 (ja) 2016-04-01 2017-03-31 Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体

Country Status (8)

Country Link
US (1) US10654861B2 (enExample)
EP (1) EP3436460B1 (enExample)
JP (1) JP6968090B2 (enExample)
CN (1) CN109195968B (enExample)
BR (1) BR112018069941A2 (enExample)
CA (1) CA3019245A1 (enExample)
EA (1) EA201892142A1 (enExample)
WO (1) WO2017167994A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
MA47106A (fr) 2016-12-21 2019-10-30 Amgen Inc Formulations d'anticorps anti-tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2020084008A1 (en) * 2018-10-24 2020-04-30 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity
CN120418259A (zh) 2022-11-23 2025-08-01 弗沃德医疗公司 TNFα活性的调节剂
TW202513567A (zh) * 2023-06-09 2025-04-01 大陸商上海翰森生物醫藥科技有限公司 五環類衍生物抑制劑、其製備方法與應用
TW202521544A (zh) 2023-08-16 2025-06-01 美商雷瑟拉股份有限公司 TNFα活性調節劑及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0408477A (pt) 2003-03-10 2006-04-04 Pfizer compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
TW200615273A (en) * 2004-11-10 2006-05-16 Nicholas Piramal India Ltd Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha
DE102008030206A1 (de) 2008-06-25 2009-12-31 Bayer Schering Pharma Aktiengesellschaft 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CN103702994B (zh) 2011-06-20 2016-03-23 沃泰克斯药物股份有限公司 旋转酶和拓扑异构酶抑制剂的磷酸酯
TR201807207T4 (tr) * 2012-06-11 2018-06-21 Ucb Biopharma Sprl Tnf-alfa modüle edici benzimidazol bileşikleri.
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
ES2689429T3 (es) 2012-07-13 2018-11-14 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de actividad de TNF
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321730D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2016050975A1 (en) * 2014-10-03 2016-04-07 Ucb Biopharma Sprl Fused pentacyclic imidazole derivatives

Also Published As

Publication number Publication date
WO2017167994A1 (en) 2017-10-05
US10654861B2 (en) 2020-05-19
US20190100525A1 (en) 2019-04-04
CN109195968A (zh) 2019-01-11
EP3436460B1 (en) 2021-08-18
CN109195968B (zh) 2022-02-11
EA201892142A1 (ru) 2019-04-30
CA3019245A1 (en) 2017-10-05
EP3436460A1 (en) 2019-02-06
JP2019512533A (ja) 2019-05-16
BR112018069941A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
JP6968092B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6968089B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合六環式イミダゾール誘導体
JP6968090B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6629847B2 (ja) 縮合五員環イミダゾール誘導体
JP7121033B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
JP6968091B2 (ja) Ｔｎｆ活性のモジュレーターとしての縮合五環式イミダゾール誘導体
EP3303337B1 (en) Fused tricyclic imidazo pyrazines as modulators of tnf activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211026

R150 Certificate of patent or registration of utility model

Ref document number: 6968090

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250